FILTER

Refine your search with the following facets to narrow down your results.

8 Current news of Gambro

New structure to strengthen growth

02-Nov-2006 - The Gambro Group will develop into three independent companies. Gambro Renal Products will become the new Gambro. Gambro Healthcare and Gambro BCT will gradually become independent companies with formal Boards of Directors and independent governance processes. When the legal reorganization is ...

Gambro and DaVita reach agreement on Amended Alliance and Product Supply Agreement

30-Aug-2006 - Gambro AB, Gambro Renal Products, Inc. and DaVita Inc. have agreed to an amended and restated Alliance and Product Supply Agreement. This amendment effectively revokes the termination notice which was provided by DaVita in May primarily as a result of Gambro Renal Products' inability to supply ...

dialysis

Jan Bruneheim new President and CEO for Gambro

20-Jul-2006 - Sören Mellstig, Gambro's current President and CEO, and Gambro's new Board of Directors have agreed on that Sören Mellstig will leave his position. Jan Bruneheim, 52, has been appointed new President and CEO for Gambro. Jan Bruneheim will take over the position August 2, 2006. Sören Mellstig ...

Gambro acquires Hemapure

11-May-2006 - Gambro announced that it intends to acquire the assets and operations of Hemapure AB. All employees will transfer to Gambro. Hemapure has developed a new innovative port system for vascular access for renal patients. Gambro will through the acquisition broaden its portfolio for vascular access ...

dialysis nephrology

Gambro and Nephrogen - new partner for regenerative medicine program

25-Oct-2005 - Gambro has recently signed an agreement with Nephrogen, LLC as part of its Regenerative Medicine initiative announced earlier this year. The program will extend over a period of three years with the target to restore the function of the kidney using adult stem cells. Initial research will focus ...

adult stem cells clinical trials regenerative medicine

Gambro expands into the emerging market for liver support

21-Sep-2004 - Gambro acquires the business of Teraklin AG, Germany, and expands its intensive care business into the extracorporeal treatments for liver support. The transaction is subject to approval by a creditors' committee of Teraklin. Teraklin develops, manufactures and markets a product line for the ...

acetaminophen dialysis Germany +5

Navigant Biotechnologies awarded additional USD 2 M Department of Defense research funding

30-Aug-2004 - Gambro's wholly owned subsidiary, Navigant Biotechnologies, Inc., announces that the U.S. Department of Defense (DOD) has awarded it an additional USD 2 million grant to continue to develop and test its Mirasol(TM) Pathogen Reduction Technology (PRT) for applications improving the safety and ...

bacteria hepatitis C malaria +6

Gambro to focus pathogen reduction development

26-Feb-2004 - Navigant Biotechnologies, Inc. ("Navigant"), a Denver, US based company and wholly owned subsidiary of Gambro AB, is focusing its Mirasol pathogen reduction technology for application to platelets and red blood cells. Pathogen reduction refers to the reduction of disease-causing viruses, bacteria ...

bacteria clinical trials plasma +3